Amyotrophic Lateral Sclerosis

Warning: Fluoroquinolone Antibiotics Linked to Nerve Damage

Study Investigating Acthar Gel in the Treatment of ALS Discontinued

Mallinckrodt has permanently discontinued the phase 2b PENNANT trial investigating Acthar Gel (repository corticotrophin) for the treatment of amyotrophic lateral sclerosis (ALS).  The study’s independent Data and Safety Monitoring Board (DSMB) recommended the trial be halted after observing a higher rate of pneumonia occurrence in Acthar-treated patients compared with those who received placebo. In addition,…